ARA-290 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What ARA-290 Does & How It Works

What It Does - Functional Outcomes

• Reduces neuropathic pain in peripheral small fiber neuropathy, including both sarcoidosis-associated and diabetic-origin neuropathy
• Promotes structural regeneration of damaged peripheral nerve fibers - measurable increases in corneal nerve fiber density confirmed in two independent Phase 2 trials
• Improves metabolic parameters including blood sugar control and lipid profiles in subjects with type 2 diabetes
• Suppresses neuroinflammation at both peripheral and central levels
• Produces effects that persist for weeks to months after a treatment course ends, without requiring continuous dosing to maintain them
• Attenuates cardiac aging markers in longitudinal animal research, including reductions in fibrosis, contractile dysfunction, and left ventricular structural deterioration

How It Works - Mechanism of Action

Selective Innate Repair Receptor (IRR) Activation (Evidence: Human and Animal)

The Innate Repair Receptor is a heterodimeric complex - meaning it is assembled from two different subunit types rather than two identical copies. It is built from one copy of the erythropoietin receptor (EPOR) paired with one copy of the beta-common receptor, also called CD131. This is structurally distinct from the EPOR homodimer - a receptor made of two identical EPOR subunits without any CD131 - which is the configuration responsible for erythropoiesis (the production of red blood cells). ARA-290's N-terminal pyroglutamate residue creates a ring structure that makes the peptide geometrically compatible only with the heterodimer configuration. It slots into the IRR and triggers tissue-protective and anti-inflammatory signaling. The erythropoietic receptor is left entirely untouched. A mechanistically important detail: IRR expression is low in healthy unstressed tissue but rapidly upregulates in response to injury, hypoxia, or metabolic stress. This means the compound preferentially acts where repair is needed.

Anti-Inflammatory Signaling Cascade (Evidence: Animal and Human)

Once the IRR is activated, ARA-290 initiates a coordinated shift in the inflammatory environment. It suppresses production of pro-inflammatory cytokines - signaling proteins that promote inflammation, specifically TNF-alpha, IL-1 beta, and IL-6 - while promoting expression of IL-10, an anti-inflammatory cytokine. It also suppresses NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), the master transcription factor that drives inflammatory gene expression across dozens of downstream targets simultaneously. In the central nervous system, this translates to dose-dependent suppression of microglial activation in the spinal cord. Microglia are the brain and spinal cord's resident immune cells, and their sustained activation is a key driver of neuropathic pain states.

TRPV1 Channel Inhibition - Independent Peripheral Mechanism (Evidence: In vitro / Animal)

ARA-290 also directly inhibits TRPV1 channels in peripheral nociceptors. TRPV1 (transient receptor potential vanilloid 1) channels are ion channels that respond to heat, acid, and inflammatory signals in pain-sensing nerve endings. This mechanism operates entirely independently of IRR activation. It is a parallel molecular pathway that addresses peripheral pain signaling at the nerve ending level. The IRR-mediated microglial suppression addresses central pain processing at the spinal cord level. The result is a two-address pain modulation profile that is mechanistically unusual among research peptides.

The Molecular Switch - Durable Effects Beyond Plasma Clearance (Evidence: Animal and Human)

ARA-290 has a plasma half-life of approximately 2 minutes by IV and approximately 20 minutes by subcutaneous injection. The compound is essentially cleared from the bloodstream within minutes to a few hours after administration. Despite this, effects documented in the Brines et al. Phase 2 trial persisted for the full 28-day post-dosing observation window with no further treatment. Preclinical rat pain models showed effects lasting up to 20 weeks after a 10-day course. The working explanation is that IRR activation functions as a molecular switch - triggering intracellular signaling cascades and gene expression changes that are self-perpetuating and maintain themselves long after the initiating peptide is gone.

ARA-290 Molecular Profile

Structure reference: View on PubChem - Publishing team: retrieve 2D structure image from this link.

ARA-290 Uses & Benefits

Sarcoidosis-Associated Small Fiber Neuropathy

Small fiber neuropathy (SFN) in sarcoidosis patients involves damage to the thin, unmyelinated nerve fibers responsible for pain and temperature sensation. People with this condition typically experience burning pain, tingling, and hypersensitivity - a distribution that often starts peripherally. ARA-290's IRR-mediated anti-inflammatory and tissue-protective signaling makes it a mechanistically rational candidate, as the IRR is expressed in peripheral nervous tissue and upregulates in response to nerve damage. Two Phase 2 trials demonstrated both symptomatic improvement and structural nerve fiber regeneration in this population, making it the application with the strongest human evidence base in ARA-290 research. (Evidence: Moderate - Dahan et al., 2013)

Diabetic Peripheral Neuropathy

Peripheral neuropathy affects a large proportion of people with long-standing type 2 diabetes and is one of the most difficult complications to treat symptomatically. The Brines et al. Phase 2 trial enrolled subjects with both type 2 diabetes and painful peripheral neuropathy, producing significant improvements in neuropathic pain scores, corneal nerve fiber density, HbA1c, lipid profiles, and quality of life measures - all within a single 28-day course, with effects persisting through a subsequent 28-day observation period. The metabolic dimension of this application makes ARA-290 relevant not only as a neuropathy research tool but as a compound with potential implications for metabolic disease research. (Evidence: Moderate - Brines et al., 2015)

Neuropathic Pain - General

Beyond the specific neuropathy populations studied in Phase 2 trials, ARA-290's dual-mechanism pain modulation - peripheral TRPV1 inhibition plus central microglial suppression - positions it as a research tool for neuropathic pain states more broadly. Preclinical characterization in rat spared nerve injury models demonstrated dose-dependent analgesia, mechanistically confirmed through CD131 knockout experiments showing complete abolition of effect when the receptor was absent. The durability of analgesic effects in preclinical models - up to 20 weeks from a 10-day course - also distinguishes it pharmacologically from standard analgesic approaches. (Evidence: Moderate for sarcoidosis SFN; Preliminary for broader neuropathic pain applications)

Cardiac Aging and Healthspan

A 15-month longitudinal rat study initiated in middle-aged animals documented that ARA-290 treatment reduced cardiac inflammatory markers, attenuated fibrosis, and reduced age-associated contractile dysfunction. Left ventricular end-systolic diameter progression - a marker of cardiac structural deterioration over time - was reduced by approximately 75% compared to saline-treated controls. In the highest-frailty animals, ejection fraction and body weight were significantly better maintained than in untreated animals. This remains a preclinical application only, with no human evidence, but it represents the most direct research examination of ARA-290's potential relevance to longevity biology. (Evidence: Preliminary - Animal)

Neuroinflammation and Autoimmune Neurological Research

In an experimental autoimmune encephalomyelitis rat model - the standard preclinical model for multiple sclerosis research - ARA-290 reduced clinical severity scores and shifted T cell populations toward Th2 and regulatory phenotypes. This extends ARA-290's immune-modulating profile beyond innate immune effects to include adaptive immune responses. Additional preclinical models have documented effects relevant to depression-like behavior, traumatic brain injury, and Parkinson's disease, all in the context of neuroinflammation as a common pathological thread. All of these represent animal-model findings only, with no human data outside the neuropathy trials. (Evidence: Preliminary - Animal - Chen et al., 2014)

Where This Guide Comes From

ARA-290 Results & Timelines

Neuropathic Pain Relief

• Week 1-2: Subtle shifts in pain quality are sometimes reported in community protocols and practitioner documentation; the controlled trials did not report week-by-week data, so early-week signal data comes primarily from real-world protocol tracking
• Week 3-4: Statistically significant improvements in neuropathic pain scores were documented at the 4-week endpoint in both the Heij pilot trial and the Brines Phase 2 trial - this is the window where the controlled trial evidence is clearest
• Week 4-8 (post-dosing): In the Brines trial, pain score improvements persisted through the 28-day post-dosing observation window without further treatment, suggesting maintained benefit well beyond the dosing period
• Beyond 8 weeks: Preclinical rat models documented analgesic effects lasting up to 20 weeks from a 10-day course; human data does not extend this far, but the molecular switch mechanism provides a biological rationale

Metabolic Improvements (HbA1c and Lipids)

• Week 1-4 (active dosing): HbA1c reflects approximately three months of blood sugar history - meaningful changes in this marker require sustained metabolic shifts and are not expected to fully manifest within a 28-day window
• By day 28-56: Significant HbA1c and lipid profile improvements were documented across the full 56-day observation window (28 days dosing plus 28 days post-dosing) in the Brines trial - improvements both emerged during the dosing period and held during the follow-up period
• Post-dosing persistence: Both metabolic markers remained improved through the end of the follow-up period, consistent with the molecular switch mechanism producing sustained metabolic effects

Structural Nerve Fiber Regeneration

• Within trial windows (approximately 4-8 weeks): Measurable increases in corneal nerve fiber density were documented in both the Dahan (2013) and Brines (2015) trials within their respective observation windows
• Full regeneration timeline: Structural nerve fiber regrowth is a slower biological process than symptom relief; the full regeneration timeline extends beyond the observation windows of published trials, and complete recovery data does not exist in the published literature
• Individual variation: Subjects with greater nerve fiber loss at baseline showed the most measurable recovery - those with near-normal baseline values showed less change, which is expected given less room for measurable improvement

How to Administer ARA-290

Subcutaneous Injection (SubQ)

Subcutaneous injection is the primary documented route in the most comprehensive Phase 2 human trials, including the Brines et al. (2015) trial that provided the most complete efficacy and safety characterization. The subcutaneous depot absorbs ARA-290 gradually, extending plasma exposure to approximately 20 minutes - substantially longer than the 2-minute plasma half-life observed after IV administration. Common subcutaneous injection sites for research peptides include the abdomen, thigh, and upper arm. Daily dosing was the protocol used in the subcutaneous Phase 2 trials.

Intramuscular Injection (IM)

Intramuscular injection has not been specifically studied for ARA-290 in published research. The compound's Phase 2 human trials used subcutaneous and intravenous routes exclusively. IM administration is not documented as a preferred or studied route for this compound, and community protocol data does not show meaningful IM use.

Nasal / Intranasal

Intranasal administration has not been studied or documented for ARA-290. Given the compound's size and the primary research route being subcutaneous injection, intranasal delivery is not a documented option for this compound.

Oral

Oral administration is not viable for ARA-290. As an 11-amino acid peptide, it is degraded by gastric acid and proteolytic enzymes in the gastrointestinal tract before it can be absorbed intact. No oral formulation has been studied, and no absorption data supporting oral bioavailability has been published. Subcutaneous injection is the practical research route.

Intravenous (IV)

Intravenous administration was used in the Heij et al. (2012) pilot trial, with a three-times-weekly dosing schedule. IV administration results in a plasma half-life of approximately 2 minutes, meaning the compound is cleared from circulation very rapidly. This route requires clinical infrastructure and is less practical for multi-day research protocols than subcutaneous injection. The transition to subcutaneous dosing in subsequent trials reflects the practical advantages of SubQ for longer treatment courses.

ARA-290 Dosage & Cycle Length

Overall dosing range: Human research has used a single fixed dose of 4 mg SC daily; preclinical animal studies used 3-100 mcg/kg depending on model and endpoint

How the goal shifts where you land:

• Low end of range: Earlier human trials and preclinical dose-finding studies used lower doses; the lower preclinical range (3-10 mcg/kg) was sufficient to produce dose-dependent effects in rat pain models
• Mid range: The 4 mg/day SC dose from the Brines et al. Phase 2 trial represents the best-characterized human research dose - the dose for which the most complete safety and efficacy data exist
• High end of range: Preclinical ischemia and cardiac studies used doses up to 100 mcg/kg; no human data exists at doses above 4 mg/day

Frequency: Once daily subcutaneous injection, based on Phase 2 human trial protocols; the earlier IV-based trial used three-times-weekly dosing

Cycle length: 28 days was the primary dosing duration in the most comprehensive human trial; the preceding pilot trial used 4 weeks of three-times-weekly IV dosing; preclinical models demonstrated that a 10-day course produced effects lasting up to 20 weeks

Post-dosing persistence: A defining feature of ARA-290 protocols is that documented biological effects - including pain reduction, HbA1c improvement, and lipid profile changes - persisted for at least 28 days after a 28-day dosing course ended in the human trial, with no further treatment given. Preclinical pain models showed effects lasting up to 20 weeks after a 10-day course. This characteristic substantially distinguishes ARA-290's dosing logic from most other peptides, where continuous administration is generally required to maintain effects.

On the 4 mg/day reference dose: This figure comes directly from the Brines et al. (2015) Phase 2 trial and is not a bodyweight-adjusted calculation - it was used as a fixed dose across the trial population. It is the only human dose with comprehensive safety monitoring, multi-endpoint efficacy data, and a formal 56-day observation window attached to it.

ARA-290 Vial Sizes, Costs & Quality

Common vial sizes: 1 mg, 2 mg, 5 mg - ARA-290 is a relatively low-volume research compound and vial size availability is narrower than for higher-demand peptides

Typical cost range: $60-$120 per vial for U.S.-manufactured research-grade ARA-290 - varies by supplier, vial size, and purity level; the relatively complex 11-amino acid sequence with a modified N-terminal residue makes synthesis more demanding than simpler peptides, which is reflected in pricing

Storage - lyophilized (dry powder):

• Temperature: Refrigerate at 2-8 degrees C; some manufacturers specify room temperature stability for short periods, but refrigeration is the standard recommendation
• Shelf life: Typically 12-24 months from manufacture date when stored correctly in lyophilized form
• Light sensitivity: Store away from direct light; amber or opaque vials are preferable

Storage - reconstituted (in solution):

• Temperature: Requires refrigeration at 2-8 degrees C after reconstitution
• Use window: Typically 14-28 days once reconstituted, depending on reconstitution solvent and storage conditions

Normal appearance after reconstitution: ARA-290 typically dissolves into a clear, colorless solution. The modified N-terminal pyroglutamate residue does not affect the visual appearance of the reconstituted peptide - the solution should be transparent with no visible particulates.

Signs of degradation: Cloudiness, visible particulates or floating material, unusual color, or off odor all indicate potential degradation. A degraded solution should not be used.

Quality Considerations

ARA-290's N-terminal pyroglutamate residue is the structural feature that defines the entire compound's pharmacology - without it, the receptor selectivity that separates ARA-290's effects from full-length EPO is gone. That makes synthesis quality unusually consequential for this specific peptide. Cutting corners in synthesis or purification does not just mean lower potency; it can mean a structurally different compound with a different receptor binding profile. Most peptides circulating online originate from overseas facilities with no standardized testing requirements and no independent verification of sequence accuracy or purity - a buyer cannot determine from appearance alone whether the pyroglutamate N-terminus is intact or whether what arrived is actually ARA-290. U.S.-manufactured research peptides come with third-party testing, documented certificates of analysis, and verifiable manufacturing processes that give a researcher confidence in what is actually in the vial.

ARA-290 Side Effects & Safety

Side Effect Spectrum

Contraindications

• Pre-existing significant renal impairment: One serious adverse event involving worsening renal insufficiency was documented in the Brines et al. trial, though confounded by a concurrent furosemide dose increase; caution is warranted in subjects with pre-existing renal disease
• Elderly subjects with significant cardiovascular comorbidities: One fatal myocardial infarction occurred in a 70-year-old male with documented comorbidities two weeks after the last dose; investigators assessed this as possibly related, though the temporal gap and patient profile complicate attribution
• Insufficient data to confirm safety in subjects with severe hepatic impairment
• No formally defined contraindications have been established - ARA-290 is not approved for therapeutic use and no regulatory-approved prescribing information exists

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data exists; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Active malignancy: Insufficient data to confirm safety; the relationship between IRR activation and tumor biology has not been formally characterized
• Subjects on nephrotoxic medications or with pre-existing renal disease: The one possibly related serious renal event in published trial data warrants caution in this population

Red Flags - Stop Use and Seek Medical Attention If:

• Significant decrease in urine output or signs of renal dysfunction
• Chest pain, shortness of breath, or cardiovascular symptoms of any kind
• Severe allergic reaction: rash extending beyond the injection site, throat tightness, or difficulty breathing
• Unusual or rapid swelling, particularly at injection sites
• Fever combined with injection site redness or warmth suggesting infection

Drug and Compound Interactions

No formal drug interaction studies have been conducted for ARA-290. The most relevant documented signal is the renal case from the Brines et al. trial, where worsening renal insufficiency occurred in a subject who concurrently received an increased dose of furosemide - a loop diuretic that can itself impair renal function. Whether ARA-290 contributed to or potentiated this renal event is unclear. Theoretical caution is warranted when combining ARA-290 with nephrotoxic agents or other compounds that place renal stress. Given ARA-290's anti-inflammatory mechanisms, interactions with immunosuppressive medications are theoretically possible but have not been characterized in any published study.

ARA-290 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability After intravenous administration, ARA-290 has a plasma half-life of approximately 2 minutes - consistent with rapid clearance typical of small linear peptides in circulation. Subcutaneous administration extends exposure significantly, with a plasma half-life of approximately 20 minutes due to slower absorption kinetics from the subcutaneous depot. Bioavailability data comparing SC to IV has not been published in formal pharmacokinetic studies; the SC route is characterized primarily through its use in multi-week clinical trials rather than dedicated pharmacokinetic studies.

Distribution Tissue distribution data for ARA-290 in humans has not been published. The relevant functional distribution is informed by the injury-selective expression pattern of the IRR - because receptor upregulation concentrates in damaged or metabolically stressed tissue, the compound's effective pharmacological activity is biased toward sites of active injury or inflammation. Whether ARA-290 crosses the blood-brain barrier has not been directly measured; its documented central effects in animal models (spinal microglia suppression) may reflect either CNS penetration or peripheral-to-central signaling propagation.

Half-Life IV: approximately 2 minutes. SC: approximately 20 minutes. Both values are consistent with the pharmacokinetics of peptides of this size and structure. Neither value explains the biological effect duration - the molecular switch mechanism is pharmacodynamic, operating through biological changes that persist after the peptide has been cleared.

Metabolism & Elimination As a peptide, ARA-290 is expected to be degraded by circulating and tissue-based proteolytic enzymes into its constituent amino acids, which then enter normal amino acid metabolism. No specific metabolic pathway or elimination route data has been published for ARA-290 in humans.

Note: Half-life values are based on limited pharmacokinetic characterization rather than formal dedicated pharmacokinetic studies. CNS penetration has not been directly measured. All metabolism data is inferred from peptide biology generally rather than ARA-290-specific studies.

Mechanistic Research

IRR-Dependent Analgesia - Knockout Model Proof (Evidence: Animal - Swartjes et al., 2011)

Rat spared nerve injury studies demonstrated dose-dependent allodynia reduction - that is, reduction in pain caused by stimuli that would not normally be painful - across a 3-60 mcg/kg range over a 10-day treatment course. The mechanistic confirmation came from CD131 knockout mice, in which ARA-290 produced zero analgesic effect - complete abolition of activity in the absence of the CD131 subunit that forms one half of the IRR. Concurrent with allodynia reduction, dose-dependent suppression of spinal cord microglia activation was documented, directly linking central neuroinflammation reduction to the observed analgesic outcome.

Durability of Effect Beyond Plasma Clearance (Evidence: Animal - Swartjes et al., 2014)

Extended follow-up in rat SNI studies documented that effects of a 10-day ARA-290 treatment course persisted for up to 20 weeks after the last dose. This duration - 14 times the length of the treatment course - is not explainable by pharmacokinetics, given that the 20-minute SC half-life means the compound is cleared within hours. The sustained effect is attributed to the molecular switch hypothesis: IRR activation triggers intracellular signaling changes and likely gene expression alterations that maintain themselves after the initiating peptide is absent.

TRPV1 Channel Inhibition - Independent Peripheral Mechanism (Evidence: In vitro / Animal - Zhang et al., 2016)

Studies in dorsal root ganglion neuron preparations demonstrated that ARA-290 directly inhibits TRPV1 channel activity - the ion channel responsible for peripheral nociceptor responses to heat, acid, and inflammatory signals in pain-sensing nerve endings. This mechanism operates independently of IRR activation and represents a parallel, complementary pathway for peripheral pain modulation. The two mechanisms together - TRPV1 inhibition peripherally and microglial suppression centrally - provide a dual anatomical address for neuropathic pain that neither mechanism achieves alone.

Autoimmune Neuroinflammation and T Cell Polarization (Evidence: Animal - Chen et al., 2014)

In the experimental autoimmune encephalomyelitis rat model - the primary animal model for multiple sclerosis research - ARA-290 reduced clinical severity scores and shifted T cell populations toward Th2 and regulatory T cell phenotypes. This finding expanded ARA-290's mechanistic profile beyond innate immune effects to include modulation of adaptive immune responses - the arm of the immune system that involves T cells and targeted, learned responses rather than general-purpose inflammation.

Depression and Neuroinflammation (Evidence: Animal - Hu et al., 2022)

In a chronic stress-induced depression model in mice, ARA-290 ameliorated depression-like behavior and reduced neuroinflammatory markers in CNS tissue. The finding is consistent with ARA-290's established microglial suppression mechanism and the well-documented role of neuroinflammation in depression pathophysiology. These are animal model findings only - no human research in psychiatric contexts has been conducted.

Condition-Focused Research

Sarcoidosis-Associated Small Fiber Neuropathy - Phase 2 Pilot Trial {#research-sfn1}

A randomized, double-blind, placebo-controlled pilot study enrolled sarcoidosis patients with small fiber neuropathy symptoms and treated them with ARA-290 intravenously three times weekly for four weeks. The Small Fiber Neuropathy Screening List score improved significantly versus placebo (p < 0.05), and the pain and physical functioning dimensions of the SF-36 quality of life measure both showed significant improvement. No laboratory abnormalities were identified during or following the dosing period. (Evidence: Moderate - human Phase 2 - Heij et al., 2012)

Sarcoidosis SFN - Structural Nerve Regeneration Confirmed {#research-sfn2}

A subsequent Phase 2 trial added a critical novel endpoint: corneal confocal microscopy to quantify nerve fiber density directly. The trial demonstrated Small Fiber Neuropathy Screening List score improvement versus placebo (p = 0.037), with approximately 80% of active-treatment subjects showing any symptom improvement and roughly 40% showing 50% or greater improvement over baseline. Corneal nerve fiber density increased measurably on confocal imaging - objective anatomical evidence of new nerve fiber growth, not merely symptom suppression. No clinically meaningful adverse events were attributable to ARA-290. (Evidence: Moderate - human Phase 2 - Dahan et al., 2013)

Type 2 Diabetes with Painful Peripheral Neuropathy - Multi-Domain Phase 2 Trial {#research-diabetes}

The most comprehensive human trial enrolled subjects with both type 2 diabetes and painful peripheral neuropathy, using 4 mg SC daily for 28 days with a 28-day post-dosing observation period. Across a 56-day total window, ARA-290 produced significant improvements in HbA1c, lipid profiles, neuropathic pain scores, corneal nerve fiber density (in subjects with below-normal baseline values), physical role functioning, and vitality. Metabolic and pain improvements persisted throughout the post-dosing period without further treatment. The mild adverse event count was numerically lower in the ARA-290 group than in placebo; four serious adverse events occurred in the treatment arm, two judged unlikely related to ARA-290 and two with uncertain causal attribution given patient comorbidities and temporal factors. No hematological changes were observed at any time point. (Evidence: Moderate - human Phase 2 - Brines et al., 2015)

Safety & Tolerability Research

Across three Phase 2 human trials - covering IV and SC routes, durations of 4-8 weeks, and populations ranging from sarcoidosis patients to subjects with type 2 diabetes - ARA-290 produced no clinically significant changes in hematological or clinical chemistry parameters at any time point. This consistently confirms that erythropoiesis is not triggered, validating the mechanistic design. Mild adverse events were reported at similar or lower frequency than placebo in the largest trial. Four serious adverse events occurred in the treatment arm of the Brines et al. trial, two with uncertain causal attribution involving elderly or renally compromised subjects, and two judged unlikely to be related. No safety signals emerged in preclinical studies including a 15-month longitudinal aging study in rats. Formal long-term safety data beyond 56-day human observation periods and Phase 3 trial safety characterization do not yet exist.

Research Limitations

ARA-290's human evidence base consists entirely of Phase 2 trials - no Phase 3 trial has been completed or published, meaning the compound has not undergone the larger-sample, multi-site confirmatory studies required for regulatory approval. The published human trials involve relatively small sample sizes, which limits statistical power to detect less common adverse events or to characterize dose-response relationships across a range of doses. All human research has focused on two specific neuropathy populations - sarcoidosis-associated SFN and diabetic peripheral neuropathy - so extrapolation to other conditions rests on mechanistic reasoning and animal data rather than clinical evidence. No dedicated pharmacokinetic study has been published in humans. Long-term safety data beyond 56 days does not exist in the human literature, and all cardiac aging, neuroinflammation, ischemia, and psychiatric applications are supported exclusively by preclinical evidence.

Is ARA-290 Legal? Regulatory & Sports Status

FDA status: ARA-290 (cibinetide) holds FDA Orphan Drug Product designation for the treatment of neuropathic pain in patients with sarcoidosis. This designation confers certain development incentives but does not constitute approval for therapeutic use. ARA-290 is not FDA-approved for any indication and is not available as a licensed pharmaceutical product in the United States as of July 2026.

Research Use: In most countries, ARA-290 is classified as a research compound without approval for human therapeutic use. Research-grade ARA-290 is available through peptide research suppliers for laboratory and investigational research contexts. Users outside formal clinical trial settings are operating outside approved use parameters.

WADA / USADA status: ARA-290 is not currently listed on the WADA Prohibited List. However, EPO and EPOR agonists are subject to close regulatory scrutiny in competitive sports, and the classification of novel EPO-derived compounds may change as testing technology advances. Athletes subject to anti-doping rules should confirm current status with WADA or their relevant anti-doping authority before any use.

Country-specific notes: Regulatory classification varies by jurisdiction. In the European Union, ARA-290 does not hold EMA approval. In Australia, it would fall under TGA jurisdiction as an unapproved therapeutic good. Users are responsible for understanding applicable regulations in their country.

Detection: No published analytical method specifically for ARA-290 detection in anti-doping contexts has been identified. Given its structural distinction from full-length EPO, standard EPO immunoassays are unlikely to detect it. However, the absence of a published detection method does not imply undetectability, particularly as testing panels expand.

ARA-290 vs. Alternatives

Commonly Paired With - Synergistic Stacks

• ARA-290 + BPC-157: Both compounds have documented anti-inflammatory and tissue-repair properties through distinct mechanisms - ARA-290 operating through the IRR and BPC-157 through VEGF upregulation and growth factor pathways. Some community researchers combine them targeting neurological and connective tissue recovery simultaneously, though no published data exists on the combination and potential interactions have not been characterized.
• ARA-290 + TB-500 (Thymosin Beta-4): TB-500 promotes actin-mediated cell migration and repair in peripheral tissues. A combination with ARA-290's IRR-mediated neuroinflammation suppression is theorized to address both the structural repair and the inflammatory environment of nerve injury recovery. No published combination data exists.
• ARA-290 + Semax or Selank: Semax and Selank are research peptides with documented neurotrophin-related and anxiolytic mechanisms. Some community researchers pair them with ARA-290 for neuroinflammatory research contexts. Evidence for the combination is absent from the published literature.

Alternatives - When Another Compound May Be Considered

Full-Length EPO (Erythropoietin) EPO is the parent molecule from which ARA-290 was derived and shares its tissue-protective and neuroprotective mechanisms. The critical distinction is that EPO also strongly stimulates erythropoiesis, driving hematocrit elevation and thrombotic risk - precisely the risk profile ARA-290 was engineered to eliminate. EPO is a licensed pharmaceutical with established clinical uses in anemia and is not appropriate as a research comparison in contexts where hematopoietic effects are undesirable.

Methylene Blue Methylene blue is studied as a mitochondrial-acting neuroprotective compound with anti-neuroinflammatory properties through different mechanisms than ARA-290. Unlike ARA-290, it is orally bioavailable, making administration substantially simpler. It does not share ARA-290's specific IRR mechanism or its documented peripheral neuropathy endpoints, and the two are not direct alternatives for specific neuropathy applications.

Cerebrolysin Cerebrolysin is a peptide mixture with documented neurotrophic and neuroprotective activity, studied in stroke, traumatic brain injury, and neurodegenerative conditions. It shares with ARA-290 a neuroprotective research profile and a requirement for injection, but operates through neurotrophic factor-like mechanisms rather than the IRR pathway. In contexts where the research goal involves acute neuroprotection or neurodegeneration, the two represent different mechanistic approaches to similar research questions.

Comparison table:

Build Your Protocol

FAQs

What is ARA-290?

ARA-290 (cibinetide) is a synthetic 11-amino acid peptide derived from the helix B surface domain of human erythropoietin (EPO). It was engineered to deliver EPO's tissue-protective effects without triggering erythropoiesis, binding selectively to the Innate Repair Receptor (IRR) rather than the erythropoietic receptor.

What does ARA-290 do?

ARA-290 activates the Innate Repair Receptor to initiate anti-inflammatory and tissue-protective signaling, and separately inhibits TRPV1 channels in peripheral pain-sensing neurons. In human clinical trials, these mechanisms have translated to reductions in neuropathic pain, measurable structural regeneration of damaged nerve fibers, and improvements in metabolic parameters including HbA1c and lipid profiles in people with diabetic neuropathy. A defining feature is that effects persist for weeks to months after a treatment course ends.

How long does ARA-290 take to work?

In the primary Phase 2 human trial, statistically significant improvements in neuropathic pain symptoms were documented over a 28-day dosing course, with the formal endpoint assessed at four weeks. Metabolic improvements including HbA1c changes take longer to manifest given that HbA1c reflects roughly three months of blood sugar history. Structural nerve fiber regeneration operates on a slower timeline still - measurable increases were documented within trial observation windows, but full recovery extends beyond the durations studied in published research.

What is the typical dose of ARA-290?

The most comprehensively characterized human research dose is 4 mg administered subcutaneously once daily for 28 days, drawn from the Brines et al. Phase 2 trial. Preclinical animal studies used weight-based dosing in the 3-100 mcg/kg range depending on the model and endpoint studied. No dose has been approved by any regulatory authority, and individual protocols should be developed with qualified guidance given the compound's research-only status.

Is ARA-290 legal?

ARA-290 holds FDA Orphan Drug designation for neuropathic pain in sarcoidosis patients but is not approved for human therapeutic use in any jurisdiction as of July 2026. It is available as a research compound through peptide suppliers but is not a licensed pharmaceutical product. It is not currently listed on the WADA Prohibited List, though athletes subject to anti-doping rules should verify current status independently given the ongoing scrutiny of EPO-related compounds.

Can ARA-290 be taken orally?

No. ARA-290 is an 11-amino acid peptide that is degraded by gastric acid and digestive enzymes in the gastrointestinal tract before it can be absorbed intact. No oral formulation has been studied or documented in the published literature. Subcutaneous injection is the practical administration route for this compound, with intravenous administration used in the earliest clinical research.

Does ARA-290 raise red blood cell count like EPO does?

No. ARA-290 was specifically engineered to avoid this effect. Full-length EPO raises red blood cell count by activating the EPOR homodimer - a receptor made of two identical EPOR subunits. ARA-290 binds only the EPOR/CD131 heterodimer - a completely different receptor configuration - and does not interact with the EPOR homodimer at all. Hematological monitoring across all Phase 2 human trials confirmed no changes in red blood cell count, hematocrit, or hemoglobin at any time point.

How long do ARA-290's effects last after stopping?

This is one of ARA-290's most pharmacologically unusual features. In the primary Phase 2 human trial, improvements in HbA1c, lipid profiles, and pain scores all persisted for the full 28-day post-dosing observation period with no further treatment. In preclinical rat pain models, a 10-day treatment course produced effects lasting up to 20 weeks after the last dose. The working explanation is that IRR activation functions as a sustained molecular switch - triggering biological changes that maintain themselves after the peptide has been cleared from the body.

What is the difference between ARA-290 and cibinetide?

They are the same compound. ARA-290 is the research name used during early development, and cibinetide is the International Nonproprietary Name (INN) assigned as the compound progressed through formal regulatory development. Both names refer to the same 11-amino acid synthetic peptide with the same sequence, mechanism, and pharmacological profile. Earlier papers in the published literature typically use ARA-290, while more recent clinical documentation increasingly uses cibinetide.

Is ARA-290 the same as the helix B surface peptide?

Yes, with one important nuance. ARA-290 is the pyroglutamate form of the helix B surface peptide - the N-terminal glutamine residue has cyclized into pyroglutamate, creating the rigid ring structure at the peptide's N-terminus that confers IRR selectivity. The term pyroglutamate helix B surface peptide (pHBSP) is used in some research literature to specifically emphasize this modification. In practice, ARA-290, cibinetide, and pHBSP all refer to the same compound.

Final Thoughts on ARA-290

ARA-290 occupies a genuinely unusual position in the research peptide landscape. It is not a general-purpose recovery compound or a longevity tool with broad but diffuse effects. It is a precision-engineered molecule built to solve a specific pharmacological problem: how to deliver erythropoietin's powerful tissue-protective signaling without triggering erythropoiesis. The solution - isolating the helix B surface domain and locking receptor selectivity through a single structural modification - is elegant, and the human clinical trial data supports the premise. Two Phase 2 trials demonstrated both symptomatic relief and structural nerve fiber regeneration in sarcoidosis-associated small fiber neuropathy. A third showed simultaneous improvements in neuropathic pain, nerve fiber density, blood sugar, and lipid profiles in diabetic peripheral neuropathy - with effects persisting for a month after the last dose. That is a meaningful clinical data set for a research compound.

The honest context is that ARA-290 has not completed Phase 3 trials. The human evidence base is Phase 2 only, meaning it lacks the sample sizes, multi-site replication, and statistical power that regulatory approval requires. The cardiac aging and neuroprotective applications that extend beyond peripheral neuropathy are built on preclinical evidence with no human confirmatory data. Long-term safety beyond 56-day observation windows is unknown. For anyone researching this compound, those gaps are part of the picture - not footnotes to be minimized.

For researchers with a specific interest in peripheral neuropathy, neuroinflammation, or the IRR pathway, ARA-290 offers something genuinely interesting: a mechanistically well-characterized compound with documented human evidence, a pharmacologically unusual durability of effect, and a structural basis for receptor selectivity that is cleaner than almost any research peptide in this category. MyPeptidePal tracks active protocols using ARA-290 and can help contextualize where current protocol data aligns with or diverges from the published trial findings - a starting point for thinking through what a research protocol actually looks like in practice.

References

1. Heij, L., Dahan, A., & Hoitsma, E. (2012). Restoration of normal blood pressure by erythropoietin in sarcoidosis patients with small fiber neuropathy. PLOS ONE, 7(12), e50940.

2. Dahan, A., Dunne, A., Swartjes, M., Proto, P. L., Heij, L., Brines, M., & Cerami, A. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine, 19(1), 334-345.

3. Brines, M., Dunne, A. N., van Velzen, M., Proto, P. L., Ostenson, C. G., Kirk, R. I., Cerami, A., & Dahan, A. (2015). ARA 290, a nonerythropoietic peptide engineered from the erythropoietin helix B surface, corrects metabolic dysfunction and improves neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine, 20(1), 658-666.

4. Swartjes, M., Mooren, R. A., Waxman, A. R., Heij, L., Schellekens, A., van Velzen, M., Brines, M., Cerami, A., Dahan, A., & Olofsen, E. (2011). ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain. Anesthesiology, 115(6), 1297-1306.

5. Swartjes, M., van Velzen, M., Niesters, M., Aarts, L., Brines, M., Cerami, A., & Dahan, A. (2014). ARA290 alleviates neuropathic pain and inflammation in a model of sarcoidosis. British Journal of Pharmacology, 171(14), 3372-3383.

6. Zhang, Y., Wang, Z., & Wu, B. (2016). ARA290 affects TRPV1 channel via IRR-independent mechanism in dorsal root ganglion neurons. Biochemical and Biophysical Research Communications, 478(3), 1302-1307.

7. Chen, M., Zhang, J., Cai, H., Ai, Y., Zou, Z., & Liang, Y. (2014). ARA290 attenuates experimental autoimmune encephalomyelitis by regulating T helper cell responses. Journal of Neuroimmunology, 277(1-2), 71-80.

8. Hu, Y., Zhang, Y., & Chen, M. (2022). ARA290 ameliorates chronic stress-induced depression-like behavior by reducing neuroinflammation. Frontiers in Pharmacology, 13, 823560.